Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 11236174 Therapeutic molecules

Patent 11236174 was granted and assigned to Crescendo Biologics Limited on February, 2022 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

0

Current Assignee

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Brian McGuinness0

Chris Rossant0

Isabelle Osuch0

Lorraine Thompson0

Michele Writer0

Mike Romanos0

Nikki Royle0

Thomas Sandal0

Date of Patent

February 1, 2022

0

Patent Application Number

160694970

Date Filed

January 12, 2017

0

Patent Citations Received

US Patent 12077595 Single domain antibodies that bind to CD137

0

US Patent 11401342 Therapeutic molecules binding PSMA

US Patent 11951172 Therapeutic molecules that bind to LAG3 and PD1

0

US Patent 11591398 Single domain antibodies to programmed cell death protein 1 (PD-1)

0

US Patent 11746158 Therapeutic molecules

US Patent 11866510 Chimeric antigen receptor with single domain antibody

0

Patent Primary Examiner

0

Patent abstract

The invention relates to binding molecules that bind specifically to prostate specific membrane antigen (PSMA), in particular, single human variable heavy chain domain antibodies and related methods for treatment of cancer.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 11236174 Therapeutic molecules

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool